Healthy volunteers help compare two ways to give experimental eczema drug
NCT ID NCT06438263
First seen Jan 26, 2026 · Last updated May 19, 2026 · Updated 16 times
Summary
This study looked at how the body absorbs rocatinlimab, an experimental drug for atopic dermatitis (eczema), when given as a single shot using an autoinjector versus a traditional vial and syringe. It involved 231 healthy adults aged 18 to 60. The goal was to see if the autoinjector delivers the drug similarly to the vial, which could make future treatments easier for patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Research Unit - Dallas
Dallas, Texas, 75247-4968, United States
-
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida, 32117-5116, United States
-
Fortrea Clinical Research Unit Inc. - Madison
Madison, Wisconsin, 53704-2526, United States
Conditions
Explore the condition pages connected to this study.